INOVIO PHARMACEUTICALS, INC. Insider Trading for March 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INOVIO PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in INOVIO PHARMACEUTICALS, INC. for March 2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 28 2017 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 6.25 | 21,300 | 133,189 | 50,000 | 28.7 K to 50 K (+74.22 %) |
| Mar 23 2017 | GEB | INOVIO PHARMACEUTI ... | Bickerstaff George | Director | Option Exercise | A | 0.00 | 12,270 | 0 | 12,270 | |
| Mar 23 2017 | GEB | INOVIO PHARMACEUTI ... | Bickerstaff George | Director | Option Exercise | A | 5.86 | 20,000 | 117,200 | 20,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | A | 0.00 | 61,300 | 0 | 61,300 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | A | 6.68 | 100,000 | 668,000 | 100,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | M | 0.00 | 25,000 | 0 | 50,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Payment of Exercise | F | 6.68 | 1,859 | 12,418 | 85,083 | 86.9 K to 85.1 K (-2.14 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Buy | M | 0.00 | 6,077 | 0 | 86,942 | 80.9 K to 86.9 K (+7.51 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Payment of Exercise | F | 6.61 | 7,648 | 50,553 | 80,865 | 88.5 K to 80.9 K (-8.64 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Buy | M | 0.00 | 25,000 | 0 | 88,513 | 63.5 K to 88.5 K (+39.36 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Option Exercise | A | 0.00 | 61,300 | 0 | 61,300 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Option Exercise | A | 6.68 | 100,000 | 668,000 | 100,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Option Exercise | M | 0.00 | 25,000 | 0 | 50,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Payment of Exercise | F | 6.61 | 7,648 | 50,553 | 43,110 | 50.8 K to 43.1 K (-15.07 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Buy | M | 0.00 | 25,000 | 0 | 50,758 | 25.8 K to 50.8 K (+97.06 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | A | 0.00 | 317,100 | 0 | 317,100 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | A | 6.68 | 43,150 | 288,242 | 43,150 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | M | 0.00 | 57,334 | 0 | 114,666 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Payment of Exercise | F | 6.68 | 52,605 | 351,401 | 2,091,297 | 2.1 M to 2.1 M (-2.45 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Buy | M | 0.00 | 139,745 | 0 | 2,143,902 | 2 M to 2.1 M (+6.97 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Payment of Exercise | F | 6.61 | 17,787 | 117,572 | 2,004,157 | 2 M to 2 M (-0.88 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Buy | M | 0.00 | 57,334 | 0 | 2,021,944 | 2 M to 2 M (+2.92 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | A | 0.00 | 61,300 | 0 | 61,300 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | A | 6.68 | 100,000 | 668,000 | 100,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | M | 0.00 | 25,000 | 0 | 50,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Payment of Exercise | F | 6.61 | 9,171 | 60,620 | 47,048 | 56.2 K to 47 K (-16.31 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Buy | M | 0.00 | 25,000 | 0 | 56,219 | 31.2 K to 56.2 K (+80.08 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | A | 0.00 | 35,000 | 0 | 35,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | A | 6.68 | 60,000 | 400,800 | 60,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | M | 0.00 | 10,000 | 0 | 20,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | M | 0.00 | 5,334 | 0 | 10,666 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Buy | M | 0.00 | 10,000 | 0 | 738,956 | 729 K to 739 K (+1.37 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Buy | M | 0.00 | 5,334 | 0 | 728,956 | 723.6 K to 729 K (+0.74 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | M | 0.00 | 8,333 | 0 | 8,333 | |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Payment of Exercise | F | 6.95 | 3,067 | 21,316 | 63,513 | 66.6 K to 63.5 K (-4.61 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Buy | M | 0.00 | 8,333 | 0 | 66,580 | 58.2 K to 66.6 K (+14.31 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | M | 0.00 | 8,333 | 0 | 8,333 | |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Payment of Exercise | F | 6.95 | 3,640 | 25,298 | 31,219 | 34.9 K to 31.2 K (-10.44 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Buy | M | 0.00 | 8,333 | 0 | 34,859 | 26.5 K to 34.9 K (+31.41 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Option Exercise | M | 0.00 | 8,333 | 0 | 8,333 | |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Payment of Exercise | F | 6.95 | 3,067 | 21,316 | 25,758 | 28.8 K to 25.8 K (-10.64 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Buy | M | 0.00 | 8,333 | 0 | 28,825 | 20.5 K to 28.8 K (+40.66 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | M | 0.00 | 13,333 | 0 | 13,333 | |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Payment of Exercise | F | 6.95 | 4,365 | 30,337 | 1,964,610 | 2 M to 2 M (-0.22 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Buy | M | 0.00 | 13,333 | 0 | 1,968,975 | 2 M to 2 M (+0.68 %) |